RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Interview With EMA’s Eric Abadie

Interview With EMA’s Eric Abadie

Posted 01 March 2011 | By

Dr. Eric Abadie is chairman of the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP). He also chairs the agency's Pharmacovigilance Working Party (PhWG) and serves as member of the Committee for Orphan Medicinal Products (COMP). Abadie has more than 25 years of experience in the pharmaceutical industry and is currently the scientific advisor to the director general of Agence française de sécurité sanitaire des produits de santé, France's national Competent Authority. In his roles with CHMP and PhWG, he is at the forefront of EMA's personalized medicine initiative. Regulatory Focus recently had the opportunity to talk with Abadie about the agency's viewpoint on this innovative approach to developing medicinal products.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.